+44 (0)1382 383219
Sarah Inglis is a clinical trial manager working in the Tayside Clinical Trials Unit. Sarah graduated BSc Physiology from University of Edinburgh in 1990 and PhD in the control of airways secretion from University of Dundee in 1994. Following a postdoc in USA Sarah returned to Dundee and obtained a Wellcome Research Career Development Fellowship. Sarah spent the next 10 years studying small airway secretions in relation to cystic fibrosis and neonatal pulmonary oedema. She moved into clinical trial work in 2009 and since then has managed a numbers of trials, including in respiratory diseases and paediatric mental health. Most recently she has run a complex portfolio of trials for Professor John Dillon, focussed around elimination of Hepatitis C from NHS Tayside.
PhD followed by Wellcome fellowship and 15 years of basic lab work into underlying causes of cystic fibrosis lung disease and neonatal pulmonary oedma.
Currently part of Professor John Dillon’s team running trials aimed at elimination of Hepatitis C from NHS Tayside.
An international study involving hundreds of Dundee children has found that the most frequently prescribed medication for the treatment of ADHD in children and adolescents is safe to use long-term